CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its ...
Moderna’s mRNA-1010 showed 26.6% higher efficacy vs. standard flu shot in adults 50+. The trial enrolled 40,805 participants across 11 countries, with mild adverse reactions reported. The market’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results